下架产品再次上架，控糖饮虚假宣传卷土重来

Core Viewpoint - The article highlights the prevalence of misleading claims regarding diabetes treatment products in China, particularly those that falsely advertise their ability to control blood sugar levels, leading to potential risks for patients [1][2]. Group 1: Misleading Product Claims - Several products, including "控糖卫液体饮" and "Breorqy西洋参苦瓜肽饮," have been found to make exaggerated claims about their effectiveness in lowering blood sugar, which are not substantiated by scientific evidence [1][2][3]. - The products are marketed as alternatives to traditional diabetes medications, with claims that they can significantly lower blood sugar levels or even allow patients to stop their medication [2][3]. Group 2: Regulatory Actions - Following the exposure of these misleading claims, the local market supervision authorities in Xiamen have initiated investigations into the companies involved, including厦门市糖逆转医学研究院 and 厦门格桑健康管理有限公司, for suspected false advertising [2][7]. - The regulatory bodies have mandated the removal of these products from online platforms and are conducting further investigations into their claims and product quality [7][9]. Group 3: Continued Sales and New Products - Despite previous removals, some products, such as "控糖卫低聚糖人参复合多肽片," have reappeared on the market with similar claims, indicating a persistent issue with compliance among sellers [3][5][9]. - New products like "瑞典控糖饮" have emerged, which also make similar unverified claims about their effectiveness in controlling blood sugar levels [6][9]. Group 4: Certification and Testing Issues - The article discusses the dubious nature of certifications provided by certain companies, such as 上海统标检测认证（集团）有限公司, which lacks the necessary credentials to validate health claims for food products [13][14]. - It emphasizes that ordinary food products cannot legally claim to prevent or treat diseases, and any certifications obtained do not provide legitimate backing for such claims [16][17].